QT Imaging Holdings
QT Imaging Holdings' revenue rose 287.9% to $19 million in fiscal 2025. Its operating margin was −23.4%, up from −249.6% a year earlier. Free cash flow was −$9 million. The diluted share count rose 57.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
QT Imaging Holdings lost money in fiscal 2025: a net loss of $21 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 225 | 0 | 0 | 1 | 10 |
| Debt incl. finance leases | — | — | 4 | 10 | 10 |
| Net debt (negative means net cash) | — | — | 4 | 9 | −0 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | 1.6x |
| Interest coverage | — | −185.3x | −22.8x | −22.6x | −10.3x |
| Current ratio | 1.8x | 0.1x | 0.7x | 0.5x | 2.8x |
| Quick ratio | 1.8x | 0.1x | 0.1x | 0.2x | 2.2x |
Cash flow
Projections
Project QT Imaging Holdings' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What QT Imaging Holdings says to expect
- Full year 2026: revenue
The Company is revising its full-year 2026 revenue guidance to approximately $34 million, from its prior guidance of approximately $39 million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $155,008 of QT Imaging Holdings shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 22, 2026 | Avi S KatzChairman, Director | Bought | 24,107 | $6.43 | $155,008 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 1 of 8 | 4 of 9 |
| Rule of 40 | — | — | 239.9% |
| Altman Z'' | −16.58 | −36.45 | −4.34 |
| Accruals ratio | −14.2% | 16.4% | −83.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | Fail | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | Fail |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | 1 of 8 | 4 of 9 |
Compare
Put QT Imaging Holdings side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| QT Imaging Holdings | FY25 | 287.9% | −23.4% | −48.0% | −130.7% | — | 4 | |
| Nephros | FY25 | 32.7% | 6.1% | — | — | — | — | Compare |
| Spectral AI | FY25 | −33.6% | −43.8% | — | — | — | — | Compare |
| Vivos Therapeutics | FY25 | 16.1% | −114.0% | −100.9% | — | — | 3 | Compare |
| Jin Medical International | FY25 | −12.0% | 2.9% | −18.0% | — | — | — | Compare |
5 years of figures
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | 0 | 0 | 5 | 19 |
| Revenue growth | — | — | — | — | 287.9% |
| Gross profit | — | — | −0 | 3 | 9 |
| Research and development | — | — | 2 | 3 | 4 |
| Operating income | −1 | −4 | −5 | −12 | −4 |
| Net income | −1 | −3 | −6 | −9 | −21 |
| Diluted EPS (US$) | −0.42 | −1.80 | −1.92 | −2.13 | −2.01 |
| Diluted shares (millions) | 3 | 2 | 3 | 7 | 10 |
| Cash flow | |||||
| Cash from operations | −1 | −1 | −3 | −10 | −9 |
| Capital expenditure | — | — | 0 | 0 | 0 |
| Free cash flow | — | — | −3 | −10 | −9 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | — | 1 | 0 | 1 |
| Balance sheet at fiscal year end | |||||
| Cash and short-term investments | 225 | 0 | 0 | 1 | 10 |
| Debt incl. finance leases | — | — | 4 | 10 | 10 |
| Total assets | 234 | 42 | 7 | 6 | 23 |
| Total liabilities | 10 | 13 | 12 | 16 | 17 |
| Shareholders' equity | −9 | −13 | −5 | −10 | 6 |
| Margins and ratios | |||||
| Gross margin | — | — | — | 54.1% | 45.4% |
| Operating margin | — | — | — | −249.6% | −23.4% |
| Net margin | — | — | — | −184.2% | −111.4% |
| Free cash flow margin | — | — | — | −207.4% | −48.0% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | 239.9% |
| Return on capital | — | — | — | — | −130.7% |
| Return on equity | — | — | — | — | — |
| Return on assets | — | −2.0% | −25.1% | −140.5% | −144.9% |
| Net debt to EBITDA | — | — | — | — | — |